

Hyloris Pharmaceuticals SA

Public limited liability company (*société anonyme/naamloze vennootschap*)
Boulevard Patience et Beaujonc 3/1
4000 Liège
Belgium
Register of legal entities: 0674.494.151 (Liège, Liège Division)
(the “**Company**”)

PROXY

The Company invites participants to be represented by a proxy holder at the annual shareholder’s meeting (the “**Annual Shareholders’ Meeting**”) that will be held:

on **9 June 2026 at 14:00 (Belgian time)**

at **Boulevard Patience et Beaujonc 3/1, 4000 Liège, Belgium.**

Please send a completed, dated and signed proxy form to the Company by no later than **3 June 2026** (date of receipt by the Company), by email to corporate@hyloris.com, or by post to Hyloris Pharmaceuticals SA, Boulevard Patience et Beaujonc 3/1, 4000 Liège, Belgium, to the attention of Mrs. Ann De Jaeger, Chief Legal Officer of the Company.

Alternatively, shareholders can use the platform of ABN AMRO Bank N.V. (“**ABN AMRO**”) (<http://www.abnamro.com/evoting>) where the shareholder can submit a proxy form with voting instructions to the Company. This electronic proxy form must be received by ABN AMRO no later than 3 June 2026.

Please note that the Company will reject proxy forms that arrive late or do not comply with the requirements set out in the convening notice.

There is no attendance quorum requirement for the deliberation and vote on the agenda items referred to in the agenda of the Annual Shareholders’ Meeting. The resolutions proposed in the agenda will be passed if a majority of the votes validly cast approves them.

This proxy is valid for any other shareholders’ meeting that is held with the same or a similar agenda as the Annual Shareholders’ Meeting that may be convened subsequently as a result of delay or adjournment. However, this only applies insofar the proxy holder has in due time complied with the required formalities to participate and vote at the subsequent meeting.

The undersigned, (name and first name or name of the company and the name, first name and function of its legal representative(s)):

residing at or having its registered office at:

-
- i. owner of _____ registered shares of the Company, for which he/she/it declares to have completed the **Formalities for Participation** set out in the convening notice (**Complete where applicable**);

- ii. owner of _____ dematerialised shares of the Company, for which he/she/it declares to have completed the **Formalities for Participation** set out in the convening notice (**Complete where applicable**);
- iii. owner of _____ registered subscription rights of the Company, for which he/she/it declares to have completed the **Formalities for Participation** set out in the convening notice (**Complete where applicable**).

Hereby appoints as proxy holder (the “**Proxy Holder**”):

- Mr. Stefan Yee, Chairman of the Board of Directors of the Company; or

- _____

(By completing this section, you will appoint a proxy holder of your choice other than the proposed proxy holder);

(Please note that if you appoint a member of the Board of Directors or any other associate or person related to the Company, by law, this person will be deemed to have a potential conflict of interest.)

(Please note that if you do not appoint a Proxy Holder, this proxy will be considered a “vote by letter”. In that case, you can no longer vote in person or by proxy at the Annual Shareholders’ Meeting.)

with power of substitution and subdelegation to represent him/her/it at the Annual Shareholders’ Meeting, which will be held on **9 June 2026 at 14:00 (Belgian time)** at **Boulevard Patience et Beaujonc 3/1, 4000 Liège, Belgium**, and to vote or abstain in his/her/its name on all the matters shown in the agenda. The Proxy Holder has the power to vote for the postponement of the Annual Shareholders’ Meeting. Furthermore, the Proxy Holder is authorized to sign on behalf of the undersigned any minutes, deeds or documents and, in general, to do everything that is necessary or useful to execute this proxy.

Please provide your voting instructions (for, against, abstain) in writing below each proposed resolution.

In the absence of voting instructions, the Proxy Holder will vote in favour of the resolutions shown on the agenda.

Notwithstanding the above, when the proposed Proxy Holder falls under the potential conflict-of-interest rules of Article 7:143, §4 of the Belgian Code on Companies and Associations (the “**BCCA**”), **you must give specific voting instructions to the proposed Proxy Holder for each of the agenda items**. If you do not give specific voting instructions for all agenda items or if, for whatever reason, there is lack of clarity on the voting instructions given, the Proxy Holder will abstain from voting. If there should be a vote on decisions to be taken by the Annual Shareholders’ Meeting, during the Annual Shareholders’ Meeting, concerning the conduct and/or organization of the Annual Shareholders’ Meeting, subject to compliance with the BCCA, the Proxy Holder will abstain from voting.

In the event of changes to the agenda and/or proposed resolutions, the Company will publish a revised agenda with additional agenda items and/or additional proposed resolutions by not later than **25 May 2026**.

Simultaneously with the publication of a revised agenda, the Company will make an amended proxy form available on the Company’s website at:

<https://hyloris.com/shareholders-meeting-2026/>

Proxy forms that have validly reached the Company prior to the publication of a revised agenda remain valid for those agenda items for which they were given. If the Company has published a revised agenda including one or more newly proposed resolutions for items that were initially mentioned on the agenda, the Proxy Holder may deviate from any instructions given by the undersigned if execution of such instructions might compromise the undersigned's interests. In that case, the Proxy Holder must inform the Principal thereof.

If the Company has published a revised agenda including one or more new agenda item(s), the Proxy Holder will abstain from voting on any new agenda items and the attendant proposed resolutions. Therefore, shareholders have the possibility to submit a new proxy by using the amended forms, in accordance with the convening notice.

ANNUAL SHAREHOLDERS' MEETING

The Annual Shareholders' Meeting will be held on 9 June 2026 at 14:00 (Belgian time) at the Company's registered office.

The applicable registration and voting formalities relating to the Annual Shareholders' Meeting are set forth in the convening notice.

Agenda Voting Instructions

- 1. Take cognizance of the Board of Directors' annual report for the financial year ending on the 31st of December 2025**

This agenda item does not require a resolution.

- 2. Take cognizance of the statutory auditor's audit report for the financial year ending on the 31st of December 2025**

This agenda item does not require a resolution.

- 3. Approve the non-consolidated annual accounts for the financial year ending on the 31st of December 2025 and approve the profit-and-loss allocation set out therein**

Proposed resolution

It is proposed to approve the non-consolidated annual accounts for the financial year ending on the 31st of December 2025 and the profit-and-loss allocation set out therein as proposed by the Board of Directors. The profit-and-loss allocation is as follows:

Loss of financial year 2025	EUR 1,205,801
Loss carried forward from the previous financial year	EUR 33,297,781
Loss to carry forward	EUR 34,503,582

<input type="checkbox"/> FOR	<input type="checkbox"/> AGAINST	<input type="checkbox"/> ABSTAIN
------------------------------	----------------------------------	----------------------------------

- 4. Take cognizance of the Board of Directors' and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2025**

This agenda item does not require a resolution.

- 5. Take cognizance of the consolidated annual accounts for the financial year ending on the 31st**

of December 2025

This agenda item does not require a resolution.

6. Grant discharge to the directors

Proposed resolution

It is proposed that discharge be granted to each director in respect of his/her/its mandate for the financial year ending on the 31st of December 2025.

<input type="checkbox"/> FOR	<input type="checkbox"/> AGAINST	<input type="checkbox"/> ABSTAIN
------------------------------	----------------------------------	----------------------------------

7. Grant discharge to the statutory auditor

Proposed Resolution

It is proposed that discharge be granted to the statutory auditor, BDO Bedrijfsrevisoren BV | BDO Réviseurs d'Entreprises SRL, represented by Mr. Christophe Pelzer, in respect of its duties for the financial year ending on the 31st of December 2025.

<input type="checkbox"/> FOR	<input type="checkbox"/> AGAINST	<input type="checkbox"/> ABSTAIN
------------------------------	----------------------------------	----------------------------------

8. Vote (advisory vote) on the remuneration report for the financial year ending on the 31st of December 2025

Proposed resolution

It is proposed to approve the remuneration report for the financial year ending on 31 December 2025, as elaborated in the annual report in the subsection *Corporate Governance – Remuneration Report (p. 85 and following)*, be approved. The 2025 annual report is available on the Company's website at <https://hyloris.com/2025-annual-report/>.

<input type="checkbox"/> FOR	<input type="checkbox"/> AGAINST	<input type="checkbox"/> ABSTAIN
------------------------------	----------------------------------	----------------------------------

9. Approve the amended remuneration policy 2026-2029

The current Remuneration Policy of was approved at the Annual Shareholders' Meeting of 11 June 2024.

Upon recommendation of the Remuneration and Nomination Committee, the Board of Directors has prepared an amended Remuneration Policy 2026-2029, which is available on the Company's website on the following address: <https://hyloris.com/shareholders-meeting-2026/> . If the Annual Shareholders' Meeting does not approve the proposed new policy, the Company will continue to remunerate its directors, other executives and day-to-day management delegates in accordance with the existing approved policy.

Proposed Resolution

It is proposed to approve the amended remuneration policy 2026-2029.

<input type="checkbox"/> FOR	<input type="checkbox"/> AGAINST	<input type="checkbox"/> ABSTAIN
------------------------------	----------------------------------	----------------------------------

10. Grant power of attorney for the performance of formalities

Proposed resolution

It is proposed that special powers be granted to Sybefica Invest BV/SRL (Vincent Van Dessel),

director, and to Marion Baine and Machias Tas (attorney with Eubelius BV/SRL) and Silke De Greef (paralegal assistant with Eubelius BV/SRL), as well as, more generally, all attorneys and paralegal assistants of Eubelius BV/SRL, to allow them to act individually, and with full power of substitution and sub-delegation, to perform in the name and on behalf of the Company all formalities pertaining to the publication obligations imposed by law regarding the resolutions adopted at the Annual Shareholders' Meeting and, more particularly, to publish an excerpt of these minutes in the Annexes to the Belgian Official Gazette and, generally, to perform all steps at the Clerk's office of the Court of Enterprises and everything necessary for these purposes.

To the extent permitted by law, the undersigned waives any liability claim against the attorney(s)-in-fact (as well as the substitutes and subdelegates) and undertakes to indemnify them for any damage they may incur because of any act carried out in relation to this power of attorney.

<input type="checkbox"/> FOR	<input type="checkbox"/> AGAINST	<input type="checkbox"/> ABSTAIN
------------------------------	----------------------------------	----------------------------------

Done at _____, on _____ 2026
by _____

(name and first name or name of the company and its legal representative(s)¹)

Signature(s):

¹ If signature on behalf of a legal entity, please specify first name, name and title of the natural person(s) signing this form on behalf of the shareholder and provide supporting documentation confirming representation powers. In the absence thereof, the natural person(s) signing this form declare(s) and certify(ies) to the Company to have the necessary powers to sign this form on behalf of the shareholder.